| 22.73 0.58 (2.62%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 27.7 | 1-year : | 32.35 |
| Resists | First : | 23.71 | Second : | 27.7 |
| Pivot price | 21.16  |
|||
| Supports | First : | 17.79 | Second : | 14.14 |
| MAs | MA(5) : | 22.26  |
MA(20) : | 19.73 |
| MA(100) : | 15.9 |
MA(250) : | 16.41 |
|
| MACD | MACD : | 1.9 |
Signal : | 1.9 |
| %K %D | K(14,3) : | 79.1 |
D(3) : | 79.9 |
| RSI | RSI(14): 69.1 |
|||
| 52-week | High : | 23.71 | Low : | 11.39 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ VRNA ] has closed below upper band by 30.8%. Bollinger Bands are 126.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 12 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 23.04 - 23.15 | 23.15 - 23.25 |
| Low: | 21.74 - 21.86 | 21.86 - 21.98 |
| Close: | 22.52 - 22.73 | 22.73 - 22.92 |
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
Fri, 26 Jul 2024
US Bancorp DE Sells 18,280 Shares of Verona Pharma plc (NASDAQ:VRNA) - Defense World
Thu, 25 Jul 2024
Verona Pharma to Report Second Quarter 2024 Financial Results and Provide Corporate Update - GlobeNewswire
Thu, 25 Jul 2024
(VRNA) Technical Data - Stock Traders Daily
Wed, 24 Jul 2024
BNP Paribas Financial Markets Has $377,000 Position in Verona Pharma plc (NASDAQ:VRNA) - Defense World
Mon, 22 Jul 2024
Verona Pharma (NASDAQ:VRNA) Price Target Increased to $37.00 by Analysts at Canaccord Genuity Group - Defense World
Thu, 20 Jun 2024
Verona Pharma: Next Week's PDUFA Date Ought To Provide An Upside Catalyst (NASDAQ:VRNA) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 81 (M) |
| Shares Float | 437 (M) |
| Held by Insiders | 3.9 (%) |
| Held by Institutions | 89.6 (%) |
| Shares Short | 8,640 (K) |
| Shares Short P.Month | 6,000 (K) |
| EPS | -0.81 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.77 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -15 % |
| Return on Equity (ttm) | -25.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.9 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -58 (M) |
| Levered Free Cash Flow | -42 (M) |
| PE Ratio | -28.42 |
| PEG Ratio | 0 |
| Price to Book value | 8.17 |
| Price to Sales | 0 |
| Price to Cash Flow | -31.75 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|